Mirvetuximab Soravtansine for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Fallopian Tube Neoplasms

Why this status

  1. 1 Jun 2012: Trial registered, NCT01609556
  2. 28 Jun 2012: Trial started, NCT01609556

The trials

NCT01609556: First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors

State
Completed
Phase
Phase 1
People
206 taking part
Started
28 Jun 2012
Primary completion
19 Mar 2018
Arms
Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W), Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly), Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W), Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W)
Results
Posted on the registry
  1. 1 Jun 2012: Trial registered
  2. 28 Jun 2012: Trial started
  3. 19 Mar 2018: Trial completed
  4. 17 Feb 2021: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as TAK-853.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.